X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs AUROBINDO PHARMA - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. AUROBINDO PHARMA FRESENIUS KABI ONCO./
AUROBINDO PHARMA
 
P/E (TTM) x 22.1 14.7 150.4% View Chart
P/BV x 3.1 3.8 81.9% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 FRESENIUS KABI ONCO.   AUROBINDO PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
AUROBINDO PHARMA
Mar-17
FRESENIUS KABI ONCO./
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs176895 19.7%   
Low Rs79622 12.6%   
Sales per share (Unadj.) Rs37.7254.6 14.8%  
Earnings per share (Unadj.) Rs5.139.3 13.0%  
Cash flow per share (Unadj.) Rs6.746.6 14.4%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs42.5160.0 26.6%  
Shares outstanding (eoy) m158.23585.88 27.0%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.43.0 113.3%   
Avg P/E ratio x25.019.3 129.4%  
P/CF ratio (eoy) x18.916.3 116.2%  
Price / Book Value ratio x3.04.7 63.1%  
Dividend payout %06.4 0.0%   
Avg Mkt Cap Rs m20,135444,390 4.5%   
No. of employees `0001.214.0 8.2%   
Total wages/salary Rs m70317,678 4.0%   
Avg. sales/employee Rs Th5,176.210,667.8 48.5%   
Avg. wages/employee Rs Th610.41,264.3 48.3%   
Avg. net profit/employee Rs Th699.61,645.8 42.5%   
INCOME DATA
Net Sales Rs m5,963149,157 4.0%  
Other income Rs m181,159 1.6%   
Total revenues Rs m5,981150,316 4.0%   
Gross profit Rs m1,43034,343 4.2%  
Depreciation Rs m2584,276 6.0%   
Interest Rs m-26667 -3.9%   
Profit before tax Rs m1,21630,558 4.0%   
Minority Interest Rs m050 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3427,597 4.5%   
Profit after tax Rs m80623,012 3.5%  
Gross profit margin %24.023.0 104.2%  
Effective tax rate %28.124.9 113.2%   
Net profit margin %13.515.4 87.6%  
BALANCE SHEET DATA
Current assets Rs m5,10292,062 5.5%   
Current liabilities Rs m2,38566,223 3.6%   
Net working cap to sales %45.617.3 262.9%  
Current ratio x2.11.4 153.8%  
Inventory Days Days150106 141.6%  
Debtors Days Days11368 167.4%  
Net fixed assets Rs m5,14862,919 8.2%   
Share capital Rs m158586 27.0%   
"Free" reserves Rs m6,55693,133 7.0%   
Net worth Rs m6,73293,719 7.2%   
Long term debt Rs m9521,814 52.5%   
Total assets Rs m10,388162,494 6.4%  
Interest coverage x-45.846.8 -97.8%   
Debt to equity ratio x0.10 730.8%  
Sales to assets ratio x0.60.9 62.5%   
Return on assets %7.514.6 51.5%  
Return on equity %12.024.6 48.8%  
Return on capital %14.632.7 44.6%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,29875,838 7.0%   
Fx outflow Rs m1,77230,224 5.9%   
Net fx Rs m3,52545,613 7.7%   
CASH FLOW
From Operations Rs m1,27432,786 3.9%  
From Investments Rs m-1,204-17,870 6.7%  
From Financial Activity Rs m-196-19,153 1.0%  
Net Cashflow Rs m-126-4,239 3.0%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 8.0 3.8%  
FIIs % 9.6 27.7 34.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.2 89.2%  
Shareholders   42,599 69,601 61.2%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   ALKEM LABORATORIES  STRIDES SHASUN LTD  FDC LTD.  ASTRAZENECA PHARMA  BIOCON LTD  

Compare FRESENIUS KABI ONCO. With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Volatile Day in Red; Pharma Stocks Lose Most(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a negative note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 0.4%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 0.4% YoY). Sales on the other hand came in at Rs 40 bn (up 11.2% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS